| Record 21504 View: Standard | Glossary HistCite Guide |
|
Author(s): Brodacki B (Brodacki, Bogdan); Staszewski J (Staszewski, Jacek); Toczylowska B (Toczylowska, Beata); Kozlowska E (Kozlowska, Ewa); Drela N (Drela, Nadzieja); Chalimoniuk M (Chalimoniuk, Malgorzata); Stepien A (Stepien, Adam)
Title: Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNF alpha, and INF gamma concentrations are elevated in patients with atypical and idiopathic parkinsonism
Source: NEUROSCIENCE LETTERS 441 (2): 158-162
Date: 2008 AUG 22
Document Type: Journal : Article
DOI: 10.1016/j.neulet.2008.06.040
Language: English
Comment:
Address: Polish Acad Sci, Med Res Ctr, Dept Cellular Signaling, PL-02106 Warsaw, Poland.
Mil Inst Hlth Serv, Dept Neurol, Warsaw, Poland. Polish Acad Sci, Inst Biochem & Biophys, PL-02106 Warsaw, Poland. Polish Acad Sci, Inst Biocybernet & Biomed Engn, PL-02106 Warsaw, Poland. Univ Warsaw, Div Biol, Dept Immunol, Warsaw, Poland. Reprint: Chalimoniuk, M, Polish Acad Sci, Med Res Ctr, Dept Cellular Signaling,
5 Pawinskiego St, PL-02106 Warsaw, Poland. E-mail: mchalim@yahoo.com
Author Keywords: cytokines; atypical parkinsonism; idiopathic Parkinson disease; serum
KeyWords Plus: PROGRESSIVE SUPRANUCLEAR PALSY; MULTIPLE SYSTEM ATROPHY; GROWTH-FACTOR-
ALPHA; NEURODEGENERATIVE DISEASES; CEREBROSPINAL-FLUID; ALZHEIMERS-
DISEASE; OXIDATIVE STRESS; GLIAL-CELLS; CYTOKINES; DIAGNOSIS
Abstract: We investigated serum levels of interleukin (IL)-2, IL-10, IL-6. IL-4, TNF alpha, INF gamma in 7 patients with atypical parkinsonism (AP), 31 idiopathic PD (iPD) patients, 17 idiopathic PD with cardiovascular risk factor (iPD-CVRF) patients, and 20 age-matched controls (healthy, non-parkinsonian patients). Cytokine concentrations were measured using the Becton Dickinson (TM) (BD (TM)) human Th1/Th2 Cytokine kit 11 with a flow cytometry system. The concentrations of IL-2, IL-10, IL-4, IL-6, TNF alpha, and INF gamma were detectable in the serum from all groups, including the control. Increased serum IL-2, IL-10, IL-4, IL-6, TNF alpha, and INF gamma concentrations were found in all groups of parkinsonian patients, as compared to the control group. The highest elevations of serum IL-2, IL-4, IL-6, TNF alpha, and INF gamma concentrations were observed in AP patients, as compared to the iPD and iPD-CVRF groups. However, the serum IL-6 concentration was higher in the iPD-CVRF group than in the iPD group. The IL-10 level was significantly higher in all groups of PD patients relative to the control group, but was the lowest in the serum from the AP patients. Moreover, the serum levels of lipid peroxidation products were enhanced 2.1 - and 1.5-fold in AP and both iPD groups, respectively. These results argue in favor of the involvement of immunological events in the process of neurodegeneration in AP and PD. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
Cited References: ASAKAWA T, 1980, LIPIDS, V15, P137 BANKS WA, 2002, NEUROIMMUNOMODULAT, V10, P319, DOI 10.1159/000071472 BARNHAM KJ, 2004, NAT REV DRUG DISCOV, V3, P205, DOI 10.1038/nrd1330 BEAL MF, 2001, NAT REV NEUROSCI, V2, P325 BRANDEL JP, 1991, NEUROSCIENCE, V41, P25 CHUNG IY, 1990, J IMMUNOL, V144, P2999 FAHN S, 2000, MERRITTS NEUROLOGY, P679 GILMAN S, 1998, J AUTONOM NERV SYST, V74, P189 HOEHN MM, 1967, NEUROLOGY, V17, P427 HORNYKIEWICZ O, 2006, J NEURAL TRANSM-SUPP, V70, P1 HOVESTADT A, 2007, PARKINSONISM PARKINS, P251 KASASHIMA S, 2003, ACTA NEUROPATHOL, V105, P117, DOI 10.1007/s00401-002-0621-x KIM SH, 2004, PARKINSONISM RELA S1, V10, PS9, DOI 10.1016/j.parkreldis.2003.11.005 KNOTT C, 2000, MOL CELL NEUROSCI, V16, P724 LANG AE, 1989, QUANTIFICATION NEURO, P285 LEE VMY, 2001, ANNU REV NEUROSCI, V24, P1121 LITVAN I, 1996, NEUROLOGY, V47, P1 LITVAN I, 2003, MOVEMENT DISORD, V18, P467, DOI 10.1002/mds.10459 MCGEER PL, 2002, J NEUROVIROL, V8, P529, DOI 10.1080/13550280290100969 MOGI M, 1994, NEUROSCI LETT, V165, P208 MOGI M, 1994, NEUROSCI LETT, V180, P147 MOGI M, 1996, NEUROSCI LETT, V211, P13 NAGATSU T, 2000, J NEURAL TRANSM-SUPP, V60, P277 ODETTI P, 2000, J NEUROPATH EXP NEUR, V59, P393 PIAO YS, 2001, ACTA NEUROPATHOL, V101, P285 RAMPELLO L, 2005, NEUROBIOL DIS, V20, P179, DOI 10.1019/j.nbd.2005.03.013 SAWADA M, 2006, J NEURAL TRANSM-SUPP, P373 SWARUP V, 2005, NEUROSCI LETT, V420 TABNER BJ, 2005, BIOCHEM SOC T 5, V33, P1082 TEISMANN P, 2003, MOVEMENT DISORD, V18, P121, DOI 10.1002/mds.10332 VILA M, 2001, CURR OPIN NEUROL, V14, P483 WAKABAYASHI K, 2006, NEUROPATHOLOGY, V26, P338, DOI 10.1111/j.1440-1789.2006.00713.x |